RxDoctor Payments Data

Michael West, MD

Clinical Cardiac Electrophysiology · Farmington, NMNPI 1902829021

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $50,000 of the $71,098 with a category attached, or 70.3%. Medtronic accounts for 79.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $23,746 and has fallen 64.1% since, to $8,518 in 2025.

$71,098in general payments, 2019–2025

Across 270 payments — averaging $263.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$57K
  • Boston Scientific$4K
  • Atricure, Inc.$2K
  • GE HealthCare$2K
  • Biosense Webster, Inc.$2K
  • Medical Device Business Services, Inc.$2K
  • plus $2K from 13 others
$219,820in research payments, 2019–2025

Across 55 payments — averaging $3996.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$220K

What the payments were for

  • Royalty or licence$50,00070%
  • Consulting fees$4,6887%
  • Travel & lodging$7,47011%
  • Food & beverage$8,94113%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$160,050
Medicare patients
1,494
Services billed
3,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban189$230,999
EliquisApixaban56$68,764
Flecainide Acetate122$4,625
Diltiazem 24hr Er (Cd)Diltiazem Hcl58$1,981
Metoprolol Succinate93$1,842
Amiodarone Hcl52$933
Atorvastatin Calcium25$407
Metoprolol Tartrate31$318
ClopidogrelClopidogrel Bisulfate14$302
Carvedilol16$281
Mupirocin21$264
Losartan Potassium13$232
Amlodipine Besylate11$212
Atenolol16$186
Prednisone13$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$183$68,76456 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Farmington

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →